ArticleBMC cardiovascular disorders2026
National trends in cardiovascular deaths with concurrent accidental drug poisoning coding in the United States: a 22-year analysis of the CDC WONDER database (1999-2020).
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWhile the overdose epidemic garners significant public health attention, cardiovascular deaths with concurrent accidental drug poisoning coding remain understudied in the United States.Traditional drug mortality surveillance primarily focuses on direct overdose fatalities, with limited integration of modern CDC-aligned multi-cause coding frameworks and atherosclerotic cardiovascular disease (ASCVD) cardiotoxicity mechanisms.We examined national trends in this phenomenon from 1999 to 2020.
methodsWe analyzed CDC WONDER data, identifying deaths where cardiovascular disease (ICD-10: I00-I99) was the underlying cause and accidental drug poisoning (ICD-10: X40-X44) was documented as a contributory cause on death certificates. Age-adjusted mortality rates (AAMR) were calculated, and trends were assessed using Joinpoint regression analysis.This study is explicitly framed as an ecological population-level surveillance analysis of death certificate co-coding patterns, rather than an assessment of individual-level drug user cardiovascular mortality risk, given the inherent general-population denominator limitation of CDC WONDER aggregate data.
resultsWe identified 33,536 deaths nationwide meeting these criteria. The AAMR nearly doubled from 0.500 to 0.979 per 100,000 population (annual percent change: +3.64%, P < 0.001). Three distinct phases emerged: rapid increase (1999-2003, + 9.746%,P < 0.001), plateau (2003-2014, + 0.843%,P = 0.188), and second increase (2014-2020, + 4.887%,P < 0.001). Significant disparities existed: mortality was 2.48 times higher in men than women, and highest among non-Hispanic Black individuals (AAMR = 1.451, 2.25 times that of non-Hispanic Whites). The West region had the highest regional mortality (AAMR = 1.165), with Nevada recording the highest state-level rate (AAMR = 3.341). Middle-aged adults(45-64 years) accounted for 60.02% of all deaths.
conclusionCardiovascular deaths with concurrent drug poisoning coding rose significantly from 1999 to 2020 in the United States, with the age-adjusted mortality rate (AAMR) increasing from 0.50 to 0.98 per 100,000 population. The trend followed three phases: a rapid rise from 1999 to 2003, a period of relative stabilization from 2003 to 2014, and another rapid increase from 2014 to 2020. Disparities were substantial and uneven: in 2020, mortality in men was approximately 2.5 times higher than in women; the highest AAMR was among non-Hispanic Black or African American individuals, and the West region carried a significantly higher risk than other regions; the 45-64 age group had the highest mortality rate, while the 25-44 age group showed a fluctuating pattern. These findings underscore the need for strengthened cardiovascular assessment and monitoring within substance-use-disorder interventions and for tailored public health strategies targeting high-risk populations and regions. At the same time, interpretations should consider limitations of death certificate coding, including potential differences in surveillance intensity and misclassification across demographic and geographic groups.All population-level trends reflect coded mortality patterns and cannot be extrapolated to individual drug-user risk, consistent with modern CDC multi-cause surveillance standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.